New pathways of treatment for psoriatic arthritis

Affiliations

Comment

Philip Mease. Lancet. 2017.

. 2017 Jun 10;389(10086):2268-2270.

doi: 10.1016/S0140-6736(17)31427-7. Epub 2017 May 24.

¹ Seattle Rheumatology Associates, Swedish Providence-St Joseph Health Systems, Seattle, WA 98122, USA. Electronic address: pmease@philipmease.com.

No abstract available

Comment on

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.